Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiscoverIE Regulatory News (DSCV)

Share Price Information for DiscoverIE (DSCV)

Share Price is delayed by 15 minutes
Get Live Data
678.00    -7.00 (-1.02%)
Bid:
665.00
Ask:
678.00
Spread: 13.00 (1.955%)
Market Cap: £658.48m
DSCV Live PriceLast checked at - London Stock Exchange

Intraday DiscoverIE Share Chart

Interim Management Statement

3 Feb 2010 07:00

RNS Number : 5762G
Acal PLC
03 February 2010
 



 

FOR RELEASE

7.00 AM

03 February 2010

 

 

ACAL plc

("Acal" or "the Group")

 

SECOND INTERIM MANAGEMENT STATEMENT

PERIOD COMMENCING 1 OCTOBER 2009

 DIRECTORATE CHANGE

 

Acal plc, a specialist provider of technology products and services across Europe and South Africa, is today issuing its second Interim Management Statement for the year ending 31 March 2010, which covers the period commencing 1 October 2009 to date and includes the quarter ended 31 December 2009.

 

The Board is pleased to report that since September 2009, trading has improved with the Group now operating profitably. The Group's balance sheet remains robust with a net cash position.

 

Electronics

 

The backlog of orders has increased at a better rate than expected, being 16% higher than the low point of April 2009, and 3% higher year on year (on a consistent basis, unadjusted for currency exchange rate movements). This is starting to translate into improved sales, which in January were around 8% higher than the previous quarter's monthly average. Orders received in the months of December and January continued at the improved level and with a positive book to bill ratio. We expect the improving sales rate to continue throughout the second half.

 

BFi Optilas ("BFi") is seeing a similar improvement. 

Supply Chain and Medical

 

As indicated in the interim results, the Supply Chain division will disengage from a major customer contract at the end of the financial year. As previously stated, losses on this contract have already been eliminated. Underlying Supply Chain sales remain stable although margins are coming under pressure.

 

Trading in the Medical division also remains stable, with sales having increased year on year. As indicated in our interim statement, spending within our UK customers in the NHS has increased in the second half of the year, although we remain cautious for the remainder of the year, as speculation of further spending cut backs continues.

 

The following material events or transactions impacted the Group during the period covered by this interim management statement.

 

Acquisition of BFi

 

On 18 December, the Group completed the acquisition of BFi for a consideration of €10 million and the issue of 2 million Ordinary Shares. The acquisition has doubled the Group's electronic sales which now account for around 70% of Group sales.

 

BFi has already exceeded our expectations in the initial period of ownership, and the process of integrating its operations with the rest of the division is progressing well.

 

Purchase and Leaseback of offices and warehouse in Eindhoven

On 31 December 2009, the Group completed the purchase, sale and leaseback of its offices and warehouse in Eindhoven. This generated a cash inflow of €0.6 million with the profit on sale being amortised over the life of the revised lease agreement.

 

Directorate Change

 

The Group also announces today that Malcolm Cooper, Group Finance Director, has resigned for personal reasons with immediate effect. Until a permanent replacement is found, Paul Neville, Group Commercial Director, will be acting Group Finance Director.

  

Nick Jefferies, Chief Executive Officer commented:

 

"The return to profitability has been achieved by taking decisive actions to reduce operating expenses and increase gross margins. Improving sales trends are now also starting to take effect. We continue to manage the business tightly, and are cautiously optimistic of a sustained improvement in market conditions.

 

We are very pleased to welcome BFi Optilas to the Acal group and are focussedon delivering the significant synergies as we build Europe's leading specialist Electronics and Photonics distributor.

 

I would like to thank Malcolm Cooper for his valuable contribution to Acal over the last ten years, and wish him well for the future."

 

 

For further information:-

 

Nicholas Jefferies ~ Chief Executive

Paul Neville ~ Group Commercial Director

 

Chris Lane / James Verstringhe

Cubitt Consulting

 

01483 544500

01483 544500

 

020 7367 5100

 

 

Notes to the Interim Management Statement

 

(a) This Interim Management Statement has been prepared solely to provide additional information to the shareholders of Acal plc, as a body, in order to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules.

 

Notes to Editors:

The Acal Group is a leading technology-based specialist distributor in Europe providing sales, marketing and other services through three Divisions: Electronics, Supply Chain and Medical. The Electronics Division distributes electronic products to industrial manufacturing and design companies. The Supply Chain Division supplies new and refurbished IT, EPOS and ATM spare parts to service providers while the Medical Division supplies advanced medical equipment to public and private healthcare providers. Acal has operating companies in the UK, Netherlands, Belgium, Germany, France, Italy, South Africa, Spain and the Nordic region.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRGDDUXGBGGD
Date   Source Headline
1st Sep 202210:17 amRNSNotification of Major Holdings
26th Aug 20222:27 pmRNSNotification of Major Holdings
22nd Aug 202210:21 amRNSNotification of Major Holdings
29th Jul 20224:23 pmRNSNotification of Major Holdings
28th Jul 20223:00 pmRNSResults of Annual General Meeting
28th Jul 20227:00 amRNSTrading Update
6th Jul 20227:00 amRNSAcquisition of the CDT group
27th Jun 20223:44 pmRNSDirector / PDMR Shareholding
24th Jun 20221:00 pmRNSAnnual Report and Notice of AGM
24th Jun 20227:00 amRNSDirector/PDMR Shareholding
22nd Jun 20229:58 amRNSDirector LTIP Award
15th Jun 20228:03 amRNSNotification of Major Holdings
14th Jun 20227:00 amRNSPreliminary results
6th Jun 20227:00 amRNSNotice of Full Year Results
19th May 20222:38 pmRNSNotification of Major Holdings
11th May 20227:00 amRNSDirector/PDMR Shareholding
9th May 20227:00 amRNSDirector/PDMR Shareholding
21st Apr 202210:57 amRNSTR-1: Notification of Major Holdings
14th Apr 20227:00 amRNSFull Year Trading Update
7th Apr 20227:00 amRNSdiscoverIE Awarded “A” Rating by MSCI ESG
29th Mar 20224:29 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSDirector Declaration
10th Mar 20223:02 pmRNSHolding(s) in Company
9th Mar 20227:00 amRNSHolding(s) in Company
4th Mar 20227:00 amRNSCompletion of Distribution Businesses Disposals
25th Feb 20229:50 amRNSDirector/PDMR Shareholding
9th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSChange to Operating Segments
10th Dec 20213:49 pmRNSDirector/PDMR Shareholding
8th Dec 20218:50 amRNSDirector/PDMR Shareholding
6th Dec 20218:30 amRNSIssue of Equity & Total Voting Rights
30th Nov 20217:00 amRNSInterim Results
22nd Nov 20214:05 pmRNSHolding(s) in Company
11th Nov 202112:49 pmRNSNotice of Half Year Results
9th Nov 20217:00 amRNSSale of Acal BFi Distribution Business
4th Nov 20217:00 amRNSAppointment of Non-Executive Director
14th Oct 20217:00 amRNSFirst Half Trading Update
4th Oct 20217:00 amRNSSale of Vertec SA
9th Sep 202110:44 amRNSHolding(s) in Company
3rd Sep 20217:00 amRNSResults of Placing
2nd Sep 20215:40 pmRNSAcquisitions & Proposed Placing
5th Aug 20215:30 pmRNSAggreko
30th Jul 20212:06 pmRNSDirector LTIP Award
29th Jul 20214:09 pmRNSResults of Annual General Meeting
29th Jul 20217:00 amRNSTrading Update
28th Jun 202110:09 amRNSHolding(s) in Company
25th Jun 20215:24 pmRNSDirector / PDMR Shareholding
16th Jun 202110:00 amRNSAnnual Report and AGM Notice
3rd Jun 20217:00 amRNSPreliminary results
18th May 20219:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.